MARSHALL WIGFALL: Open Payments
NPI 1629306139 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$770 in 32 payments from 5 companies in 2025. Trend: 2023 $284 · 2024 $527 · 2025 $770
Food & beverage: $770
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $340 |
| Otsuka America Pharmaceutical, Inc. | 7 | $246 |
| Vanda Pharmaceuticals Inc. | 11 | $146 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: CAPLYTA, REXULTI, FANAPT, ABILIFY ASIMTUFII, HETLIOZ, COBENFY, UZEDY, ABILIFY MAINTENA.
Industry payments across VA — which companies pay providers there.
